These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 22950536)
1. Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma. Hoy SM Drugs; 2012 Oct; 72(14):1929-50. PubMed ID: 22950536 [TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
3. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Dennie TW; Kolesar JM Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042 [TBL] [Abstract][Full Text] [Related]
5. Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia. Vidal L; Gafter-Gvili A; Gurion R; Raanani P; Dreyling M; Shpilberg O Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009045. PubMed ID: 22972131 [TBL] [Abstract][Full Text] [Related]
6. Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Garnock-Jones KP Drugs; 2010 Sep; 70(13):1703-18. PubMed ID: 20731477 [TBL] [Abstract][Full Text] [Related]
7. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Elefante A; Czuczman MS Am J Health Syst Pharm; 2010 May; 67(9):713-23. PubMed ID: 20410545 [TBL] [Abstract][Full Text] [Related]
8. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain. Sanchez-Gonzalez B; Peñalver FJ; Medina A; Guillén H; Calleja M; Gironella M; Arranz R; Sebastian E; de Oña R; Cánovas A; de la Fuente I; Grande C; Sancho JM; Perez R; Domingo E; Lopez-Lorenzo JL; Prieto E; Panizo C; Gorosquieta A; Perez I; Cervera JM; Marin M; Mencha C; Ramila E; Salar A Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023 [TBL] [Abstract][Full Text] [Related]
9. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Keating GM Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951 [TBL] [Abstract][Full Text] [Related]
10. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. Bremer K J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial. Ujjani C; Cheson B Future Oncol; 2011 Jan; 7(1):9-14. PubMed ID: 21174533 [TBL] [Abstract][Full Text] [Related]
12. Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas. Weide R; Heymanns J; Gores A; Köppler H Leuk Lymphoma; 2002 Feb; 43(2):327-31. PubMed ID: 11999564 [TBL] [Abstract][Full Text] [Related]
13. Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma. Plosker GL; Carter NJ Drugs; 2008; 68(18):2645-60. PubMed ID: 19093705 [TBL] [Abstract][Full Text] [Related]
14. BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA. Bogeljić Patekar M; Milunović V; Mišura Jakobac K; Perica D; Mandac Rogulj I; Kursar M; Planinc-Peraica A; Ostojić Kolonić S Acta Clin Croat; 2018 Sep; 57(3):542-553. PubMed ID: 31168188 [TBL] [Abstract][Full Text] [Related]
16. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. García Muñoz R; Izquierdo-Gil A; Muñoz A; Roldan-Galiacho V; Rabasa P; Panizo C Ann Hematol; 2014 Nov; 93(11):1879-87. PubMed ID: 24951124 [TBL] [Abstract][Full Text] [Related]
17. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Cheson BD; Friedberg JW; Kahl BS; Van der Jagt RH; Tremmel L Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):452-7. PubMed ID: 21189660 [TBL] [Abstract][Full Text] [Related]
18. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W; Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739 [TBL] [Abstract][Full Text] [Related]